Emphysematous lung sealant (ELS) therapy reduces CRP, an index of inflammation, in patients with severe emphysema (clinicaltrials.gov #NCT NCT00884962)
E. Ingenito, O. Fruchter, F. Herth, R. Eberhardt, A. Valipour, S. Asadi, R. Bonnet, I. Maeder, A. Kempa, F. Stanzel, M. Kramer (Woburn, United States Of America; Petach Tikva, Israel; Heidelberg, Bad Berka, Hemer, Germany; Vienna, Austria)
Source: Annual Congress 2013 –Bronchoscopic treatment of COPD and asthma: where are we going?
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Ingenito, O. Fruchter, F. Herth, R. Eberhardt, A. Valipour, S. Asadi, R. Bonnet, I. Maeder, A. Kempa, F. Stanzel, M. Kramer (Woburn, United States Of America; Petach Tikva, Israel; Heidelberg, Bad Berka, Hemer, Germany; Vienna, Austria). Emphysematous lung sealant (ELS) therapy reduces CRP, an index of inflammation, in patients with severe emphysema (clinicaltrials.gov #NCT NCT00884962). Eur Respir J 2013; 42: Suppl. 57, 2295
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: